RBO & Co. LLC Has $22.93 Million Stake in Kenvue Inc. (NYSE:KVUE)

RBO & Co. LLC lifted its holdings in Kenvue Inc. (NYSE:KVUE) by 40.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 991,419 shares of the company’s stock after purchasing an additional 286,929 shares during the period. Kenvue accounts for approximately 3.6% of RBO & Co. LLC’s portfolio, making the stock its 8th biggest holding. RBO & Co. LLC’s holdings in Kenvue were worth $22,932,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KVUE. Leo Wealth LLC raised its holdings in shares of Kenvue by 0.3% in the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after buying an additional 481 shares in the last quarter. Massmutual Trust Co. FSB ADV grew its position in Kenvue by 6.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after acquiring an additional 492 shares during the period. Wolff Wiese Magana LLC raised its stake in Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares in the last quarter. Marathon Capital Management lifted its holdings in shares of Kenvue by 0.3% during the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after acquiring an additional 514 shares during the period. Finally, Poehling Capital Management INC. boosted its stake in shares of Kenvue by 0.5% in the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after purchasing an additional 547 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of KVUE stock opened at $24.12 on Wednesday. The firm has a market cap of $46.24 billion, a price-to-earnings ratio of 43.85, a PEG ratio of 2.20 and a beta of 1.36. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $22.87 and a 200 day moving average price of $20.92.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the previous year, the company earned $0.31 EPS. Kenvue’s revenue was down .4% on a year-over-year basis. Research analysts expect that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. The ex-dividend date is Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on KVUE. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Piper Sandler boosted their target price on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a report on Monday, September 23rd. Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a research report on Tuesday, September 24th. Finally, UBS Group raised their target price on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.